PTGS2 and MMP9 had the highest amplification rates, with DCRGs amplified in bladder cancer, esophagogastric cancer, ovarian cancer, head and neck cancer, and breast cancer (Figure 5D). Here, MMP9 is linked to ovarian carcinoma.